1.35
+0.05(+3.85%)
Currency In USD
| Previous Close | 1.3 |
| Open | 1.29 |
| Day High | 1.35 |
| Day Low | 1.2 |
| 52-Week High | 4.4 |
| 52-Week Low | 0.85 |
| Volume | 24,483 |
| Average Volume | 25,507 |
| Market Cap | 21,719 |
| PE | -0.52 |
| EPS | -2.58 |
| Moving Average 50 Days | 1.3 |
| Moving Average 200 Days | 1.8 |
| Change | 0.05 |
If you invested $1000 in Akari Therapeutics, Plc (AKTX) 10 years ago, it would be worth $13.78 as of June 02, 2025 at a share price of $1.35. Whereas If you bought $1000 worth of Akari Therapeutics, Plc (AKTX) shares 5 years ago, it would be worth $31.4 as of June 02, 2025 at a share price of $1.35.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Akari Therapeutics Releases “Meet the Team” Video Featuring Recently Appointed Mark F. Kubik, Head of Business Development – Oncology
GlobeNewswire Inc.
May 29, 2025 1:15 PM GMT
Well-established industry leader whose oncology expertise and transactions record has led to multiple approved therapeutic products and advanced clinical product candidatesAccess the video here BOSTON and LONDON, May 29, 2025 (GLOBE NEWSWIRE) -- Ak
Akari Therapeutics to Present at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar
GlobeNewswire Inc.
May 22, 2025 1:00 PM GMT
Live webcast on Thursday, May 29th at 2:20 PM ETBOSTON and LONDON, May 22, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing novel payload antibody drug conjugates (ADCs), today announced
Akari Therapeutics Appoints Mark F. Kubik as Head of Business Development - Oncology
GlobeNewswire Inc.
May 01, 2025 12:45 PM GMT
Global expertise in establishing and executing transformative transactions which have led to multiple approved therapeutic products Successful track record across oncology therapeutics including ADCs and antibody therapies ranging from early discover